Erratum to ‘Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?’ [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100796]
Saved in:
| Main Authors: | Mariona Riudavets, MD, PhD, David Planchard, MD, PhD |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | JTO Clinical and Research Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666364325000566 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting DLL3: A New Weapon in Lung Neuroendocrine Tumors?
by: Mariona Riudavets, MD, PhD, et al.
Published: (2025-05-01) -
Erratum to ‘Model-Based Cost-Utility Analysis of Combined Low-Dose Computed Tomography Screening for Lung Cancer, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease’ [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100813]
by: Carina M. Behr, PhD, et al.
Published: (2025-07-01) -
Erratum to ‘Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC’ [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100815]
by: Federico Cappuzzo, MD, et al.
Published: (2025-07-01) -
Corrigendum to ‘Humanized Mouse Models for Immuno-Oncology Research: A Review and Implications in Lung Cancer Research’ [JTO Clinical and Research Reports Volume 6 Issue 3 (2025) 100781]
by: Cheol-Kyu Park, MD, PhD, et al.
Published: (2025-05-01) -
First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report
by: Alissa J. Cooper, MD, et al.
Published: (2024-12-01)